Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.

Buisman FE, Homs MYV, Grünhagen DJ, Filipe WF, Bennink RJ, Besselink MGH, Borel Rinkes IHM, Bruijnen RCG, Cercek A, D'Angelica MI, van Delden OM, Donswijk ML, van Doorn L, Doornebosch PG, Emmering J, Erdmann JI, IJzerman NS, Grootscholten C, Hagendoorn J, Kemeny NE, Kingham TP, Klompenhouwer EG, Kok NFM, Koolen S, Kuhlmann KFD, Kuiper MC, Lam MGE, Mathijssen RHJ, Moelker A, Oomen-de Hoop E, Punt CJA, Te Riele WW, Roodhart JML, Swijnenburg RJ, Prevoo W, Tanis PJ, Vermaas M, Versleijen MWJ, Veuger FP, Weterman MJ, Verhoef C, Groot Koerkamp B.

BMC Cancer. 2019 Apr 5;19(1):327. doi: 10.1186/s12885-019-5515-6.

2.

Hypermorphic and hypomorphic AARS alleles in patients with CMT2N expand clinical and molecular heterogeneities.

Weterman MAJ, Kuo M, Kenter SB, Gordillo S, Karjosukarso DW, Takase R, Bronk M, Oprescu S, van Ruissen F, Witteveen RJW, Bienfait HME, Breuning M, Verhamme C, Hou YM, de Visser M, Antonellis A, Baas F.

Hum Mol Genet. 2018 Dec 1;27(23):4036-4050. doi: 10.1093/hmg/ddy290.

PMID:
30124830
3.

Images of God and attitudes towards death in relation to spiritual wellbeing: an exploratory side study of the EORTC QLQ-SWB32 validation study in palliative cancer patients.

Kruizinga R, Scherer-Rath M, Schilderman JBAM, Weterman M, Young T, van Laarhoven HWM.

BMC Palliat Care. 2017 Dec 8;16(1):67. doi: 10.1186/s12904-017-0251-7.

4.

A phase Ib study of everolimus combined with metformin for patients with advanced cancer.

Molenaar RJ, van de Venne T, Weterman MJ, Mathot RA, Klümpen HJ, Richel DJ, Wilmink JW.

Invest New Drugs. 2018 Feb;36(1):53-61. doi: 10.1007/s10637-017-0478-4. Epub 2017 Jun 15.

5.

LRSAM1-mediated ubiquitylation is disrupted in axonal Charcot-Marie-Tooth disease 2P.

Hakonen JE, Sorrentino V, Avagliano Trezza R, de Wissel MB, van den Berg M, Bleijlevens B, van Ruissen F, Distel B, Baas F, Zelcer N, Weterman MAJ.

Hum Mol Genet. 2017 Jun 1;26(11):2034-2041. doi: 10.1093/hmg/ddx089.

PMID:
28335037
6.

Deregulated expression of EZH2 in congenital brainstem disconnection.

Barth PG, Aronica E, Fox S, Fluiter K, Weterman MAJ, Poretti A, Miller DC, Boltshauser E, Harding B, Santi M, Baas F.

Neuropathol Appl Neurobiol. 2017 Jun;43(4):358-365. doi: 10.1111/nan.12368. No abstract available.

PMID:
27886392
7.

A LRSAM1 mutation links Charcot-Marie-Tooth type 2 to Parkinson's disease.

Aerts MB, Weterman MA, Quadri M, Schelhaas HJ, Bloem BR, Esselink RA, Baas F, Bonifati V, van de Warrenburg BP.

Ann Clin Transl Neurol. 2015 Dec 22;3(2):146-9. doi: 10.1002/acn3.281. eCollection 2016 Feb.

8.

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW.

Lancet Oncol. 2015 Jul;16(7):839-47. doi: 10.1016/S1470-2045(15)00027-3. Epub 2015 Jun 8.

PMID:
26067687
9.

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.

Kordes S, Klümpen HJ, Weterman MJ, Schellens JH, Richel DJ, Wilmink JW.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1135-41. doi: 10.1007/s00280-015-2730-y. Epub 2015 Mar 31.

10.

CLP1 founder mutation links tRNA splicing and maturation to cerebellar development and neurodegeneration.

Schaffer AE, Eggens VR, Caglayan AO, Reuter MS, Scott E, Coufal NG, Silhavy JL, Xue Y, Kayserili H, Yasuno K, Rosti RO, Abdellateef M, Caglar C, Kasher PR, Cazemier JL, Weterman MA, Cantagrel V, Cai N, Zweier C, Altunoglu U, Satkin NB, Aktar F, Tuysuz B, Yalcinkaya C, Caksen H, Bilguvar K, Fu XD, Trotta CR, Gabriel S, Reis A, Gunel M, Baas F, Gleeson JG.

Cell. 2014 Apr 24;157(3):651-63. doi: 10.1016/j.cell.2014.03.049.

11.

Recessive MYL2 mutations cause infantile type I muscle fibre disease and cardiomyopathy.

Weterman MA, Barth PG, van Spaendonck-Zwarts KY, Aronica E, Poll-The BT, Brouwer OF, van Tintelen JP, Qahar Z, Bradley EJ, de Wissel M, Salviati L, Angelini C, van den Heuvel L, Thomasse YE, Backx AP, Nürnberg G, Nürnberg P, Baas F.

Brain. 2013 Jan;136(Pt 1):282-93. doi: 10.1093/brain/aws293.

PMID:
23365102
12.

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.

Kordes S, Richel DJ, Klümpen HJ, Weterman MJ, Stevens AJ, Wilmink JW.

Invest New Drugs. 2013 Feb;31(1):85-91. doi: 10.1007/s10637-012-9802-1. Epub 2012 Feb 25.

13.

A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy.

Weterman MA, Sorrentino V, Kasher PR, Jakobs ME, van Engelen BG, Fluiter K, de Wissel MB, Sizarov A, Nürnberg G, Nürnberg P, Zelcer N, Schelhaas HJ, Baas F.

Hum Mol Genet. 2012 Jan 15;21(2):358-70. doi: 10.1093/hmg/ddr471. Epub 2011 Oct 19.

14.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4. Epub 2011 Aug 2.

15.

Mechanisms for nonrecurrent genomic rearrangements associated with CMT1A or HNPP: rare CNVs as a cause for missing heritability.

Zhang F, Seeman P, Liu P, Weterman MA, Gonzaga-Jauregui C, Towne CF, Batish SD, De Vriendt E, De Jonghe P, Rautenstrauss B, Krause KH, Khajavi M, Posadka J, Vandenberghe A, Palau F, Van Maldergem L, Baas F, Timmerman V, Lupski JR.

Am J Hum Genet. 2010 Jun 11;86(6):892-903. doi: 10.1016/j.ajhg.2010.05.001. Epub 2010 May 20.

16.

Copy number variation upstream of PMP22 in Charcot-Marie-Tooth disease.

Weterman MA, van Ruissen F, de Wissel M, Bordewijk L, Samijn JP, van der Pol WL, Meggouh F, Baas F.

Eur J Hum Genet. 2010 Apr;18(4):421-8. doi: 10.1038/ejhg.2009.186. Epub 2009 Nov 4.

17.

LAD-1/variant syndrome is caused by mutations in FERMT3.

Kuijpers TW, van de Vijver E, Weterman MA, de Boer M, Tool AT, van den Berg TK, Moser M, Jakobs ME, Seeger K, Sanal O, Unal S, Cetin M, Roos D, Verhoeven AJ, Baas F.

Blood. 2009 May 7;113(19):4740-6. doi: 10.1182/blood-2008-10-182154. Epub 2008 Dec 8.

18.

tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia.

Budde BS, Namavar Y, Barth PG, Poll-The BT, Nürnberg G, Becker C, van Ruissen F, Weterman MA, Fluiter K, te Beek ET, Aronica E, van der Knaap MS, Höhne W, Toliat MR, Crow YJ, Steinling M, Voit T, Roelenso F, Brussel W, Brockmann K, Kyllerman M, Boltshauser E, Hammersen G, Willemsen M, Basel-Vanagaite L, Krägeloh-Mann I, de Vries LS, Sztriha L, Muntoni F, Ferrie CD, Battini R, Hennekam RC, Grillo E, Beemer FA, Stoets LM, Wollnik B, Nürnberg P, Baas F.

Nat Genet. 2008 Sep;40(9):1113-8. doi: 10.1038/ng.204.

PMID:
18711368
19.

Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival.

Milne AN, Carvalho R, Jansen M, Kranenbarg EK, van de Velde CJ, Morsink FM, Musler AR, Weterman MA, Offerhaus GJ.

J Clin Pathol. 2008 Mar;61(3):311-6. doi: 10.1136/jcp.2006.042648.

PMID:
18305181
20.

Genetic defects underlying Peutz-Jeghers syndrome (PJS) and exclusion of the polarity-associated MARK/Par1 gene family as potential PJS candidates.

de Leng WW, Jansen M, Carvalho R, Polak M, Musler AR, Milne AN, Keller JJ, Menko FH, de Rooij FW, Iacobuzio-Donahue CA, Giardiello FM, Weterman MA, Offerhaus GJ.

Clin Genet. 2007 Dec;72(6):568-73. Epub 2007 Oct 9.

21.

Peutz-Jeghers syndrome polyps are polyclonal with expanded progenitor cell compartment.

de Leng WW, Jansen M, Keller JJ, de Gijsel M, Milne AN, Morsink FH, Weterman MA, Iacobuzio-Donahue CA, Clevers HC, Giardiello FM, Offerhaus GJ.

Gut. 2007 Oct;56(10):1475-6. No abstract available.

22.

Pontine tegmental cap dysplasia: a novel brain malformation with a defect in axonal guidance.

Barth PG, Majoie CB, Caan MW, Weterman MA, Kyllerman M, Smit LM, Kaplan RA, Haas RH, Baas F, Cobben JM, Poll-The BT.

Brain. 2007 Sep;130(Pt 9):2258-66. Epub 2007 Aug 9.

PMID:
17690130
23.

Phenotype of Charcot-Marie-Tooth disease Type 2.

Bienfait HM, Baas F, Koelman JH, de Haan RJ, van Engelen BG, Gabreëls-Festen AA, Ongerboer de Visser BW, Meggouh F, Weterman MA, De Jonghe P, Timmerman V, de Visser M.

Neurology. 2007 May 15;68(20):1658-67.

PMID:
17502546
24.

Molecular analysis of primary gastric cancer, corresponding xenografts, and 2 novel gastric carcinoma cell lines reveals novel alterations in gastric carcinogenesis.

Milne AN, Sitarz R, Carvalho R, Polak MM, Ligtenberg M, Pauwels P, Offerhaus GJ, Weterman MA.

Hum Pathol. 2007 Jun;38(6):903-13. Epub 2007 Mar 21.

PMID:
17376510
25.

Charcot-Marie-Tooth disease due to a de novo mutation of the RAB7 gene.

Meggouh F, Bienfait HM, Weterman MA, de Visser M, Baas F.

Neurology. 2006 Oct 24;67(8):1476-8.

PMID:
17060578
27.

Nasal polyposis in Peutz-Jeghers syndrome: a distinct histopathological and molecular genetic entity.

de Leng WW, Westerman AM, Weterman MA, Jansen M, van Dekken H, Giardiello FM, de Rooij FW, Paul Wilson JH, Offerhaus GJ, Keller JJ.

J Clin Pathol. 2007 Apr;60(4):392-6. Epub 2006 Jun 14.

28.

STRAD in Peutz-Jeghers syndrome and sporadic cancers.

de Leng WW, Keller JJ, Luiten S, Musler AR, Jansen M, Baas AF, de Rooij FW, Gille JJ, Menko FH, Offerhaus GJ, Weterman MA.

J Clin Pathol. 2005 Oct;58(10):1091-5.

29.

Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas.

Carvalho R, Milne AN, Polak M, Corver WE, Offerhaus GJ, Weterman MA.

Oncogene. 2005 Dec 15;24(56):8252-8.

PMID:
16091737
30.

Do collision tumors of the gastroesophageal junction exist? A molecular analysis.

Milne AN, Carvalho R, van Rees BP, van Lanschot JJ, Offerhaus GJ, Weterman MA.

Am J Surg Pathol. 2004 Nov;28(11):1492-8.

PMID:
15489653
31.

Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age.

Carvalho R, Milne AN, van Rees BP, Caspers E, Cirnes L, Figueiredo C, Offerhaus GJ, Weterman MA.

J Pathol. 2004 Sep;204(1):75-83.

PMID:
15307140
32.

Ductuloinsular tumors of the pancreas: endocrine tumors with entrapped nonneoplastic ductules.

van Eeden S, de Leng WW, Offerhaus GJ, Morsink FH, Weterman MA, de Krijger RR, Klöppel G, Klimstra DS.

Am J Surg Pathol. 2004 Jun;28(6):813-20.

PMID:
15166675
33.

Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas.

De Leng WW, Westerman AM, Weterman MA, De Rooij FW, Dekken Hv Hv, De Goeij AF, Gruber SB, Wilson JH, Offerhaus GJ, Giardiello FM, Keller JJ.

Clin Cancer Res. 2003 Aug 1;9(8):3065-72.

34.

DNA copy number changes in young gastric cancer patients with special reference to chromosome 19.

Varis A, van Rees B, Weterman M, Ristimäki A, Offerhaus J, Knuutila S.

Br J Cancer. 2003 Jun 16;88(12):1914-9.

35.

Different pattern of allelic loss in Epstein-Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathway.

van Rees BP, Caspers E, zur Hausen A, van den Brule A, Drillenburg P, Weterman MA, Offerhaus GJ.

Am J Pathol. 2002 Oct;161(4):1207-13.

36.

Understanding familial and non-familial renal cell cancer.

Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG.

Hum Mol Genet. 2002 Oct 1;11(20):2489-98. Review.

PMID:
12351585
37.

Molecular genetic evidence of an association between nasal polyposis and the Peutz-Jeghers syndrome.

Keller JJ, Westerman AM, de Rooij FW, Wilson JH, van Dekken H, Giardiello FM, Weterman MA, Offerhaus GJ.

Ann Intern Med. 2002 Jun 4;136(11):855-6. No abstract available.

PMID:
12044140
38.

Cytogenetic and molecular analysis of early stage renal cell carcinomas in a family with a translocation (2;3)(q35;q21).

Bodmer D, Eleveld M, Ligtenberg M, Weterman M, van der Meijden A, Koolen M, Hulsbergen-van der Kaa C, Smits A, Smeets D, Geurts van Kessel A.

Cancer Genet Cytogenet. 2002 Apr 1;134(1):6-12.

PMID:
11996788
39.

Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21).

Bodmer D, Eleveld M, Kater-Baats E, Janssen I, Janssen B, Weterman M, Schoenmakers E, Nickerson M, Linehan M, Zbar B, van Kessel AG.

Hum Mol Genet. 2002 Mar 15;11(6):641-9.

PMID:
11912179
40.

Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas.

Weterman MA, van Groningen JJ, Tertoolen L, van Kessel AG.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13808-13.

41.

Genomic structure, chromosomal localization, and embryonic expression of the mouse homolog of PRCC, a gene associated with papillary renal cell carcinoma.

Weterman MA, Wilbrink M, Eleveld M, Merkx G, van Groningen JJ, van Rooijen M, Geurts van Kessel A.

Cytogenet Cell Genet. 2001;92(3-4):326-32.

PMID:
11435707
42.

Fusion of a novel gene, RCC17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinomas.

Heimann P, El Housni H, Ogur G, Weterman MA, Petty EM, Vassart G.

Cancer Res. 2001 May 15;61(10):4130-5.

43.

Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes.

Weterman MA, van Groningen JJ, den Hartog A, Geurts van Kessel A.

Oncogene. 2001 Mar 22;20(12):1414-24.

44.

Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15).

Eleveld MJ, Bodmer D, Merkx G, Siepman A, Sprenger SH, Weterman MA, Ligtenberg MJ, Kamp J, Stapper W, Jeuken JW, Smeets D, Smits A, Geurts Van Kessel A.

Genes Chromosomes Cancer. 2001 May;31(1):23-32.

PMID:
11284032
45.
46.

Renal cell cancer: chromosome 3 translocations as risk factors.

van Kessel AG, Wijnhoven H, Bodmer D, Eleveld M, Kiemeney L, Mulders P, Weterman M, Ligtenberg M, Smeets D, Smits A.

J Natl Cancer Inst. 1999 Jul 7;91(13):1159-60. No abstract available.

PMID:
10393725
47.

An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation.

Bodmer D, Eleveld MJ, Ligtenberg MJ, Weterman MA, Janssen BA, Smeets DF, de Wit PE, van den Berg A, van den Berg E, Koolen MI, Geurts van Kessel A.

Am J Hum Genet. 1998 Jun;62(6):1475-83.

48.

Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas.

Weterman MA, Wilbrink M, Geurts van Kessel A.

Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15294-8.

49.

Fine mapping of the 1q21 breakpoint of the papillary renal cell carcinoma-associated (X;1) translocation.

Weterman MA, Wilbrink M, Dijkhuizen T, van den Berg E, Geurts van Kessel A.

Hum Genet. 1996 Jul;98(1):16-21.

PMID:
8682500
50.

Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts.

Degen WG, Weterman MA, van Groningen JJ, Cornelissen IM, Lemmers JP, Agterbos MA, Geurts van Kessel A, Swart GW, Bloemers HP.

Int J Cancer. 1996 Feb 8;65(4):460-5.

Supplemental Content

Loading ...
Support Center